Significant Insider Buying Reverses neutral Trend over Last 90 Days in Shares of Kala Pharmaceuticals (KALA)

Friday, January 12, 2018 10:15 PM ET

Significant Insider Buying Reverses neutral Trend over Last 90 Days in Shares of Kala Pharmaceuticals (KALA)

Substantial insider buying activity was disclosed in Kala Pharmaceuticals shares in a form 4 document filed with the SEC today, showing — ORBIMED ADVISORS LLC, 10% Owner — acquired 240,484 shares in the company having a net market value of approximately $3,192,710. This is the first insider buy/sell trade in the past 90 days.

Kala Pharmaceuticals buy-sell trading activity is close to the 280 member peer company average. The Bio Therapeutic Drugs peer group saw 336 buy/sell trades during this period for an average of 1.2 transactions per company. However, trading at Kala Pharmaceuticals represents a lower number of shares per transaction. Within the peer group there were 46,184,815 shares purchased and 40,770,209 shares sold with company insiders having bought 24,724 shares on average over this time period.

Significant insider buying and selling activity has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in data sourced in composing and writing this story.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2018 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.